Biocentury reported that mid-sized biotech companies are being pressured to accept MFN pricing deals modeled for big pharma, with the core consideration centering on payer mix and tariff exposure. The coverage frames MFN arrangements as complex to price and harder for smaller developers to negotiate without compromising commercial positioning. For biotech operators, the story connects pricing mechanics to balance-sheet constraints at a time when companies increasingly rely on de-risked assets, partnered development, and time-sensitive reimbursement pathways to fund pipeline expansion.